Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospita...
SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseases Phase 1b trial to...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, announced that it has...
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fas...
-The PPD™ clinical research business of Thermo Fisher Scientific, the world leader in serving science, announced a new research and development (R&...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...
Kynexis, a clinical-stage biotechnology company focused on precision therapeutics for brain diseases, announced that the first patient has been dosed in ...
VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH,...
Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable d...
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-1...
Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, announces the official openin...
Global pharma major Lupin Limited (Lupin), announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisi...
Approved for use in the earliest symptomatic stages, Kisunla is the only once-monthly amyloid plaque–targeting therapy with evidence supporting tre...
© 2025 Biopharma Boardroom. All Rights Reserved.
